Dergiler / Acta Medica / 2022 / Cilt: 53 - Sayı: 1

CRISPR-based Approaches for the Point-of-Care Diagnosis of COVID19

Sayfa
1–14
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In terms of clinical validation, SHERLOCK, STOPCovid, and DETECTR were the most extensively studied ones and they are also reported to be highly sensitive and specific compared to RT-qPCR.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2), is a novel Betacoronavirus variant that emerged in December 2019 causing the coronavirus disease 19 (COVID19) pandemic.
📊
Temel Bulgular & Veri:Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) is currently the golden standard for the diagnosis of COVID19 worldwide.
💡
Sonuç & Katkı:In terms of clinical validation, SHERLOCK, STOPCovid, and DETECTR were the most extensively studied ones and they are also reported to be highly sensitive and specific compared to RT-qPCR.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2019 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2), is a novel Betacoronavirus variant that emerged in December 2019 causing the coronavirus disease 19 (COVID19) pandemic. It is reported that asymptomatic and presymptomatic individuals can transmit the virus and this silent transmission has been a major obstacle for the control of the pandemic. To overcome this obstacle, widespread testing with a rapid turnaround time is required. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) is currently the golden standard for the diagnosis of COVID19 worldwide. Even though RT-qPCR is an efficient method in terms of sensitivity and specificity, the need for elaborate instrumentation and skilled personnel restricts its widespread use. Restriction of RT-qPCR to a limited number of laboratories makes it further time-consuming. Many approaches are present to address the requirement for a rapid and accurate COVID19 diagnosis. In this review, different CRISPR-based approaches for the point-of-care diagnosis of COVID19 are compared. Among these approaches, CRISPR-FDS on- chip assay is found to be the best option as it is reported to be highly sensitive and specific, has a short turnaround time (15 min), does not need RNA isolation or special tools, and simple to perform. In terms of clinical validation, SHERLOCK, STOPCovid, and DETECTR were the most extensively studied ones and they are also reported to be highly sensitive and specific compared to RT-qPCR.

🔖

Bu Makaleye Atıf Yap

Uzay, İ. A., Dinçer, P. (2022). CRISPR-based Approaches for the Point-of-Care Diagnosis of COVID19. Acta Medica, Cilt: 53 - Sayı: 1, 1–14. https://ajindex.com/articles/427506

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. 1] Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020;382:727-33. [2] Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565- 74. [3] Zhang YZ, Holmes EC. A Genomic Perspective on the Origin and Emergence of SARS-CoV-2. Cell 2020;181:223- 7. [4] Chan JFW, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;395:514-23. [5] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506. [6] Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus- Infected Pneumonia in Wuhan, China JAMA | Original Investigation | CARING FOR THE CRITICALLY ILL PATIENT. JAMA 2020;323:1061-9. [7] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (CoVID-19) from publicly reported confirmed cases: Estimation and application. Ann Intern Med 2020;172:577-82. [8] Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis 2020;20:411-2. [9] Tong ZD, Tang A, Li KF, et al. Potential presymptomatic transmission of SARS-CoV-2, Zhejiang Province, China, 2020. Emerg Infect Dis 2020;26:1052-4. [10] Ye F, Xu S, Rong Z, et al. Delivery of infection from asymptomatic carriers of COVID-19 in a familial cluster. Int J Infect Dis 2020;94:133-8. [11] He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020;26:672-5. [12] Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med 2020;382:1177-9. [13] Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA - J Am Med Assoc 2020;323:1406-7. [14] Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J Med 2020;382:970-1. [15] Huff H V, Singh A. Asymptomatic Transmission During the Coronavirus Disease 2019 Pandemic and Implications for Public Health Strategies. Clin Infect Dis 2020;71:2752-6. [16] Nuccetelli M, Pieri M, Grelli S, et al. SARS-CoV-2 infection serology: a useful tool to overcome lockdown? Cell Death Discov 2020;6:1-9. [17]